Structure Therapeutics CMO has 11,826 shares withheld

Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition.

Accepted by SEC EDGAR 03/05/2026 - 06:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition. On the vesting of a restricted share unit award, 11,826 Ordinary Shares were withheld by the company at $20.99 per share to cover income tax obligations. After this withholding transaction, Blas directly owned 204,981 Ordinary Shares. The footnotes explain that each American Depositary Share represents three Ordinary Shares.

Insider Trade Summary

Exercise Price or Tax Liability: 11,826 shares

Exercise Price or Tax Liability 1 txn

Insider Coll Crespo Blas

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	11,826	$20.99	$248K

Holdings After Transaction: Ordinary Shares — 204,981 shares (Direct)

Holdings Before and After: Ordinary Shares, 216,807 to 204,981 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Structure Therapeutics (GPCR) report for Coll Crespo Blas?

Structure Therapeutics reported that chief medical officer Coll Crespo Blas had 11,826 Ordinary Shares withheld to cover taxes on a restricted share unit vesting. This Form 4 disposition reflects a tax-withholding event rather than an open-market trade.

How many Structure Therapeutics (GPCR) shares were disposed of in this Form 4?

The Form 4 shows a disposition of 11,826 Ordinary Shares at $20.99 per share. These shares were withheld by Structure Therapeutics to satisfy income tax obligations arising from the vesting of a restricted share unit award for the chief medical officer.

Was the Structure Therapeutics (GPCR) insider transaction an open-market sale?

No, the transaction was not an open-market sale. The Form 4 describes a tax-withholding disposition, where 11,826 shares were withheld by Structure Therapeutics to pay income taxes linked to restricted share unit vesting, rather than shares being sold on the open market.

How many Structure Therapeutics (GPCR) shares does Coll Crespo Blas hold after the transaction?

After the tax-withholding disposition, Coll Crespo Blas directly owned 204,981 Ordinary Shares of Structure Therapeutics. This post-transaction balance reflects holdings following the withholding of 11,826 shares to cover income tax obligations on a restricted share unit vesting event.

What does the Form 4 say about Structure Therapeutics (GPCR) ADS and Ordinary Share ratio?

The filing explains that Structure Therapeutics’ Ordinary Shares may be represented by American Depositary Shares. Each ADS represents three Ordinary Shares, providing investors with a clear conversion ratio between ADSs traded in depositary form and the underlying Ordinary Shares.

Why were shares withheld in the Structure Therapeutics (GPCR) Form 4 transaction?

Shares were withheld to satisfy income tax obligations from the vesting of a restricted share unit award. Instead of paying cash taxes, 11,826 Ordinary Shares were retained by Structure Therapeutics, a common mechanism to cover tax liabilities on equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coll Crespo Blas

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		F		11,826(2)	D	$20.99	204,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.